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Abstract 18 
KSHV is the causative agent of commonly fatal malignancies of immuno-compromised 19 
individuals, including primary effusion lymphoma (PEL) and Kaposi’s sarcoma (KS). A hallmark of 20 
all herpesviruses is their biphasic lifecycle – viral latency and the productive lytic cycle, and it is 21 
well established that reactivation of the KSHV lytic cycle is associated with KS pathogenesis. 22 
Therefore, a thorough appreciation of the mechanisms that govern reactivation is required to 23 
better understand disease progression. The viral protein, replication and transcription activator 24 
(RTA), is the KSHV lytic switch protein due to its ability to drive the expression of various lytic 25 
genes, leading to reactivation of the entire lytic cycle. While the mechanisms for activating lytic 26 
gene expression have received much attention, how RTA impacts on cellular function is less 27 
well understood. To address this, we developed a cell line with doxycycline-inducible RTA 28 
expression and applied SILAC-based quantitative proteomics. Using this methodology, we have 29 
identified a novel cellular protein (AT-rich interacting domain containing 3B, ARID3B) whose 30 
expression was enhanced by RTA and that relocalised to replication compartments upon lytic 31 
reactivation. We also show that siRNA knockdown or overexpression of ARID3B led to an 32 
enhancement or inhibition of lytic reactivation, respectively. Furthermore, DNA affinity and 33 
chromatin immunoprecipitation assays demonstrated that ARID3B specifically interacts with 34 
A/T-rich elements in the KSHV origin of lytic replication (oriLyt), and this was dependent on lytic 35 
cycle reactivation. Therefore, we have identified a novel cellular protein whose expression is 36 
enhanced by KSHV RTA with the ability to inhibit KSHV reactivation.  37 
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Importance 38 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of fatal malignancies of 39 
immunocompromised individuals, including Kaposi’s sarcoma (KS). Herpesviruses are able to 40 
establish a latent infection, where they escape immune detection by restricting viral gene 41 
expression. Importantly however, reactivation of productive viral replication (the lytic cycle) is 42 
necessary for the pathogenesis of KS. Therefore, it is important that we comprehensively 43 
understand the mechanisms that govern lytic reactivation, to better understand disease 44 
progression. In this study, we have identified a novel cellular protein (AT-rich interacting 45 
domain protein 3B, ARID3B) that we show is able to temper lytic reactivation.  We showed that 46 
the master lytic switch protein, RTA, enhanced ARID3B levels, which then interacted with viral 47 
DNA in a lytic cycle dependent manner. Therefore, we have added a new factor to the list of 48 
cellular proteins that regulate the KSHV lytic cycle, which has implications for our 49 
understanding of KSHV biology. 50 
  51 
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Introduction 52 
Infection of immune-compromised people with Kaposi’s sarcoma-associated herpesvirus (KSHV) 53 
is frequently linked with fatal malignancies. It is well established as the causative agent of 54 
primary effusion lymphoma (PEL) and Kaposi’s sarcoma (KS) and is often associated with 55 
multicentric Castleman’s disease (MCD) (1, 2). Like all herpesviruses, KSHV infection is lifelong 56 
and has two distinct phases to its life cycle; latency and the lytic cycle. Latency is associated 57 
with a highly restrictive viral gene expression program involving the latency-associated nuclear 58 
antigen (LANA), viral FLICE inhibitory protein (vFLIP), viral cyclin, kaposin and various virally-59 
encoded miRNAs and together, these are required for maintenance of the KSHV genome in 60 
vitro (3) and tumorigenesis in vivo (2). However, reactivation from latency to the lytic cycle is 61 
indispensable for the pathogenesis of KS; indeed active virus replication and increased viral 62 
loads are associated with poorer clinical outcomes (4-6) and, there is clinical evidence that 63 
treatment of patients with ganciclovir (inhibitor of herpesvirus replication) significantly reduces 64 
the incidence of KS (7). Therefore, a comprehensive understanding of molecular mechanisms 65 
that govern KSHV reactivation is critical to our understanding of disease progression. 66 
Expression of a single viral protein, replication and transcriptional activator (RTA), is both 67 
necessary and sufficient for reactivation of the KSHV lytic cycle (reviewed in (8)). In vitro, RTA 68 
expression is stimulated by certain cellular cues such as plasma cell differentiation (9, 10) and 69 
hypoxia (11), and because RTA autoactivates its own promoter and drives the full lytic cycle, it 70 
is well established as the true KSHV lytic-switch protein (8). RTA activates transcription of lytic 71 
genes by directly interacting with RTA-responsive elements (RREs) found in some lytic gene 72 
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promoters, or indirectly via interactions with cellular transcription factors, particularly RBP-Jκ, 73 
AP-1 and Oct-1 (8). The RTA protein comprises all the elements that one would expect for a 74 
transcriptional activator, such as nuclear localization signals (NLS), a DNA binding domain (DBD) 75 
and a transcriptional activation (TA) domain. Further functional domains have also been 76 
identified, such as a leucine zipper domain that is important for homo-tetramer formation (12), 77 
a serine/threonine-rich region that is subject to phosphorylation (13) and a multitude of binding 78 
sites for various protein-protein interactions (PPIs) (8). 79 
The best characterized lytic promoters that are dependent on the direct DNA binding 80 
mechanism are the PAN and K12 promoters (14, 15). Both genes are highly expressed during 81 
lytic reactivation, but their expression is prevented when DNA binding mutants of RTA are 82 
expressed (15). Furthermore, transfection experiments with plasmids containing the PAN 83 
promoter showed that RTA was essential for activating transcription, as mRNA was 84 
undetectable in its absence (16). The sequence elements that were found to be RTA-responsive 85 
demonstrated significant homology between the PAN and K12 promoters, and centered on an 86 
A/T-rich trinucleotides (17) reminiscent of interferon-stimulated response elements found in 87 
the promoters of interferon-dependent genes (18).  88 
There are several lytic genes that are activated via the indirect mechanism, including the RTA 89 
gene itself (ORF50), ORF57 (Mta), ORF6, ORF74 (vGCPR), K6 (vMIP-1), and ORF73 (LANA) (15, 19, 90 
20). However, whether RTA’s intrinsic DNA binding property is important for the activation of 91 
promoters via the indirect mechanism is a contentious issue. While some view that RTA’s ability 92 
to transactivate the ORF57 promoter is completely dependent on PPIs (15), others suggest that 93 
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cooperation between RTA-DNA interactions and PPIs enhances the activation of transcription. 94 
For example, in addition to the essential RBP-Jκ binding site found in the ORF57 promoter, RTA 95 
binding sites have been identified that surround this region that have been characterized as 96 
partial palindromes of A/T-rich elements with a 5’-CANT-3’ (N = any nucleotide) repeat core 97 
element (21). Extensive analysis of this promoter element suggested a model whereby RTA 98 
recruits RBP-Jκ to its consensus binding sequence, and through tetramer formation, RTA makes 99 
contacts with its cognate CANT-repeats (21). Furthermore, stabilization of this complex may 100 
occur via further upstream CANT-repeat interactions involving additional cellular transcription 101 
factors, such as AP-1 (8). 102 
RTA is also required to coordinate lytic replication of the KSHV genome at the cis-acting origins 103 
of lytic replication (oriLyt). For example, it is responsible for docking the viral pre-replication 104 
complex at the oriLyt (22), and this process, for unknown reasons, requires RTA-mediated 105 
transcription of an oriLyt-associated transcript (23, 24). Two distinct oriLyt sequences have 106 
been identified in the KSHV genome (oriLyt left and right); interestingly, RREs in oriLyt left share 107 
significant homology to those found in the PAN and K12 promoters (23). Furthermore, oriLyt 108 
contains an A/T-rich region consisting of various palindromic sequences in addition to a highly 109 
G/C-rich repeat element. Interestingly, DNA affinity studies have demonstrated that several 110 
cellular proteins preferentially interact with oriLyt via its A/T-rich regions (25). 111 
Unlike most other herpesviruses, de novo infection of cells lines with KSHV leads to latency 112 
where the viral genome is rapidly chromatinized and lytic genes are associated with repressive 113 
histone modifications (26-28), making KSHV an amenable model for studying the establishment 114 
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of herpesvirus latency. Furthermore, reactivation of the lytic cycle promotes various negative 115 
feedback mechanisms that serve to temper lytic gene expression during reactivation and, in 116 
vivo, these presumably function to promote the establishment or maintenance of latency. 117 
These include viral factors (e.g. LANA (29, 30) and viral miRNAs (31)) and cellular proteins (e.g. 118 
NF-κB (32), TLE2 (33), PARP-1 (34) and HDAC1 (35)) which have been found to temper RTA 119 
transactivation of its target promoters and thus reactivation of the lytic cycle. Clearly, silencing 120 
of KSHV lytic gene expression, or inhibition of lytic DNA replication, is an important step in the 121 
life cycle of KSHV. Nevertheless, the mechanisms that are involved are poorly understood.   122 
To begin to gain an understanding of how RTA expression impacts on the cellular proteome, we 123 
employed a global quantitative proteomics approach using stable isotope labeling of amino 124 
acids in cell culture coupled to tandem mass spectrometry (SILAC-MS/MS). Quantitative 125 
proteomics, using various platforms, is a powerful method that has been employed by various 126 
laboratories, including our own (36-38), to investigate virus-host interactions (recently 127 
reviewed in (39) and (40)). Using this approach we identified a novel protein, A/T-rich 128 
interacting domain 3B (ARID3B), whose expression was enhanced by RTA and that regulated 129 
the KSHV lytic cycle. ARID3B, so called as it contains an A/T-rich interactive domain (ARID), 130 
belongs to a family of proteins involved in the regulation of gene expression. The ARID of 131 
ARID3A (a paralogue of ARID3B that functions as a B cell activator) has been shown to 132 
preferentially bind AATTAA sequences (41, 42); as this domain shares 89.9% sequence identity 133 
with that found in ARID3B, it suggests there is functional conservation between these proteins.   134 
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As a transcription factor (43, 44), ARID3B promotes survival during development (44-46), and it 135 
is these properties that link it with various malignancies (43, 47-52). Very little else is known 136 
about ARID3B; however, we reasoned that its prosurvival properties may be important during 137 
the KSHV lytic cycle and it might promote lytic gene expression, thus explaining its RTA-138 
mediated enhanced expression. However, we found that ARID3B inhibited lytic reactivation, 139 
and, as it preferentially bound to regions containing A/T-rich elements in oriLyt, we consider 140 
the possibility that it either prevents oriLyt-dependent gene expression or it blocks access to 141 
proteins essential for viral genome replication.  142 
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Materials and Methods 143 
Cell lines, plasmids and transfections. TREx-BCBL-1-RTA cells (a kind gift from Dr. Jae Jung, 144 
University of Southern California) are a BCBL-1-based cell line that has been engineered to 145 
inducibly express exogenous Myc-tagged RTA by the addition of 1 µg/ml doxycycline hyclate, 146 
leading to a robust reactivation of the full KSHV lytic cycle (53); these were cultured in RPMI-147 
1640 (Lonza) supplemented with 10% FBS (Life Technologies). Inducible SLK-BAC16 cells (iSLK-148 
BAC16; also a gift from Dr. Jae Jung) were grown in DMEM (Lonza) supplemented with 10% FBS 149 
(Life Technologies). These maintain a latent infection with bacterial artificial chromosome 16- 150 
(BAC16)-derived KSHV (54). The parental SLK cell line, originally considered to be KSHV-negative 151 
endothelial cells derived from a KS patient, were subsequently found to be a contaminant of a 152 
renal carcinoma cell line Caki1 (55). Nevertheless, they are widely used as a model for the study 153 
of KSHV biology. Initially, these cells were engineered to inducibly express RTA (iSLK) following 154 
the addition of doxycycline (56) and subsequently transfected with BAC16 and selected based 155 
on BAC-derived puromycin resistance (54). This cell line was demonstrated to support an 156 
authentic latent infection, and induction of the lytic cycle (with 1 µg/ml doxycycline hyclate) 157 
leads to the release of infectious virus (54).  158 
HEK 293T cells were used for reinfection assays as previously described (57). HEK293 rKSHV.219 159 
cells (58) maintains KSHV as a latent infection and was generated by infecting HEK293T cells 160 
with a recombinant KSHV that contains a constitutively active puromycin resistance and GFP 161 
gene, and an RFP gene that is fused to an RTA-responsive lytic cycle (PAN) promoter (not 162 
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utilized in this study). Both HEK 293T-based cell lines were maintained in DMEM (Lonza) 163 
supplemented with 10% FBS (Life Technologies). 164 
To generate cells with inducible N-terminal FLAG-His-tagged RTA expression (iRTA-293), RTA 165 
was amplified from pRTS-ORF50 (14) (forward primer: 5’-166 
ATCTTAAGGCCACCATGGATTATAAAGATGACGATGACAAGCATCATCATCATCATCATGCGCAAGATG167 
ACAAGGGTAAG-3’, reverse primer: 5’-ATCTCGAGTCAGTCTCGGAAGTAATTACG-3’) and ligated in 168 
to the AflI-XhoI sites of pcDNA5-FRT-TO (Life Technologies) to generate pcDNA5-FH-RTA. 169 
Functionality of this vector was demonstrated due to its ability to reactivate the KSHV lytic cycle 170 
following its transfection. Flp-In-293 cells (Life Technologies) were transfected along with 171 
pOG44 (flp recombinase) and subsequently selected using Hygromycin B following the 172 
manufacturer’s protocol (Life Technologies). Clonal populations were generated by limiting 173 
dilution under Hygromycin B selection and clones with tightly regulated expression and normal 174 
growth properties (compared to parental cells) were selected. RTA expression was induced 175 
following treatment with 1 µg/ml doxycycline hyclate for the indicated times. iRTA-293 cells 176 
were maintained in DMEM (Lonza) supplemented with 10% FBS (Life Technologies).  177 
The vector expressing C-terminally FLAG-tagged ARID3B was generated by PCR amplification 178 
using an ARID3B-containing plasmid (kind gift from Dr. Karen Cowden Dahl, Indiana University) 179 
as template (Forward primer: 5’-CGCGGATCCAAGCGATGGAGCCACTTCAGCAGCAGCAGCA-3’, 180 
reverse primer: 5’-181 
CGCGAATTCTCACTTATCGTCGTCATCCTTGTAATCGAGGGACCAGCTGGTGGAGGGCTC-3’). Products 182 
were digested and ligated into the BamHI and EcoRI sites of pcDNA3 (pcDNA3-ARID3B-FLAG). 183 
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FLAG-tagged SRAG was a kind gift from Prof Stuart Wilson (University of Sheffield). Expression 184 
constructs were verified by DNA sequencing. 185 
For transfections, cells were plated into 6-well plates and transfections routinely used 1 μg 186 
plasmid DNA and Lipofectamine 2000 (Life Technologies) following the manufacturer’s 187 
instructions.  188 
To determine the effects of overexpressed proteins on virus reactivation efficiencies, iSLK-189 
BAC16 cells were transfected for 24 h and the lytic cycle was induced by doxycycline treatment 190 
for a further 24 h. Samples were processed for immunoblot analysis (see later).  191 
Stable isotope labelling of amino acids in cell culture (SILAC)-proteomics. iRTA-293 cells were 192 
grown in “heavy”-labeled media containing stable isotopes of arginine (R) and lysine (K) (R10K8; 193 
DMEM-16, Dundee Cell Products) or “light”-labeled media (R0K0; DMEM-14, Dundee Cell 194 
Products) supplemented with 10% dialysed FCS (DS1003, Dundee Cell Products) for two weeks.  195 
Cells were grown to 80-90% confluency in 10 cm dishes that included poly-L-lysine coated 196 
coverslips, used to verify RTA expression by immunofluorescence (see later). RTA expression 197 
was induced for 12 h following treatment of heavy-labeled cells with 1 µg/ml doxycycline 198 
hyclate. To reduce sample complexity, and to investigate how RTA expression impacts on the 199 
nuclear proteome, labeled cells were fractionated (verified by immunoblotting; see later). After 200 
rinsing the monolayer with PBS, 1x107 cells from each culture were lysed in 5 ml cytoplasmic 201 
lysis buffer  containing 20 mM Tris (pH 7.4), 100 mM NaCl, 0.5 mM EDTA, 0.5 % NP-40 and 1x 202 
protease inhibitor cocktail (Roche) for 20 min at 4°C. The nuclei were pelleted at 2000 xg for 5 203 
min at 4°C and the cytoplasmic fraction was removed and stored. Nuclei were washed three 204 
 o
n
 August 22, 2016 by UNIVERSITY O
F LEEDS
http://jvi.asm.org/
D
ow
nloaded from
 
12 
 
times in cytoplasmic lysis buffer, then nuclear proteins were extracted using 200 µl RIPA buffer 205 
by repeated pipetting and storage on ice for 15 min. Insoluble material was pelleted at 12,000 206 
xg for 10 min and the supernatant was removed.  207 
Equal amounts of protein from unlabeled and labeled samples were combined prior to protein 208 
digestion. Briefly, samples were reduced 50 mM DTT 1x NUPAGE LDS loading buffer, and then 209 
separated by one-dimensional SDS-PAGE (4-12% Bis-Tris Novex mini-gel, Life Technologies) and 210 
visualized by colloidal Coomassie staining (Novex, Life Technologies). The entire protein gel 211 
lanes were excised and cut into 10 slices each. Every gel slice was subjected to in-gel digestion 212 
with trypsin overnight at 37°C. The resulting tryptic peptides were extracted by formic acid (1%) 213 
and acetonitile, lyophilized in a speed vac and resuspended in 1% formic acid. Trypsin-digested 214 
peptides were separated using an Ultimate 3000 RSLC (Thermo Scientific) nanoflow LC system. 215 
On average 0.5 µg was loaded with a constant flow of 5 µl/min onto an Acclaim PepMap100 216 
nanoViper C18 trap column (100 µm inner diameter, 2cm; Themro Scientific). After trap 217 
enrichment, peptides were eluted onto an Acclaim PepMap RSLC nanoViper, C18 column (75 218 
µm, 15 cm; Thermo Scientific) with a linear gradient of 2–40% solvent B (80% acetonitrile with 219 
0.08% formic acid) over 65 min with a constant flow of 300 nl/min. The HPLC system was 220 
coupled to a linear ion trap Orbitrap hybrid mass spectrometer (LTQ Orbitrap Velos, Thermo 221 
Scientific) via a nano-electrospray ion source (Thermo Scientific). The spray voltage was set to 222 
1.2 kV, and the temperature of the heated capillary was set to 250°C. Full-scan MS survey 223 
spectra (m/z 335–1800) in profile mode were acquired in the Orbitrap with a resolution of 224 
60,000 after accumulation of 1,000,000 ions. The fifteen most intense peptide ions from the 225 
preview scan in the Orbitrap were fragmented by collision-induced dissociation (normalized 226 
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collision energy, 35%; activation Q, 0.250; and activation time, 10 ms) in the LTQ after the 227 
accumulation of 10,000 ions. Maximal filling times were 1,000 ms for the full scans and 150 ms 228 
for the MS/MS scans. Precursor ion charge state screening was enabled, and all unassigned 229 
charge states as well as singly charged species were rejected. The lock mass option was enabled 230 
for survey scans to improve mass accuracy. Data were acquired using the Xcalibur software. The 231 
raw mass spectrometric data files obtained for each experiment were collated into a single 232 
quantitated data set using MaxQuant (version 1.2.2.5) and the Andromeda search engine 233 
software . Enzyme specificity was set to that of trypsin, allowing for cleavage N-terminal to 234 
proline residues and between aspartic acid and proline residues. Other parameters used were: 235 
(i) variable modifications, methionine oxidation, protein N-acetylation, Gln to pyro-Glu; (ii) fixed 236 
modifications, cysteine carbamidomethylation; (iii) database: target-decoy human MaxQuant 237 
(ipi.HUMAN.v3.68); (iv) heavy labels: R10K8; (v) MS/MS tolerance: FTMS- 10 ppm , ITMS- 0.6 Da; 238 
(vi) maximum peptide length, 6; (vii) maximum missed cleavages, 2; (viii) maximum of labelled 239 
amino acids, 3; and (ix) false discovery rate (FDR), 1%. Peptide ratios were calculated for each 240 
arginine- and/or lysine-containing peptide as the peak area of labelled arginine/lysine divided 241 
by the peak area of nonlabelled arginine/lysine for each single-scan mass spectrum. Peptide 242 
ratios for all arginine- and lysine-containing peptides sequenced for each protein were 243 
averaged. Data were normalized using 1/median ratio value for each identified protein group 244 
per labelled sample. Pathway analysis was performed using DAVID Bioinformatics Resources 245 
[https://david.ncifcrf.gov/] (59, 60) using proteins that were at least 2-fold differences. 246 
Immunoprecipitation and Immunoblotting. Immunoprecipitation assays have been described 247 
previously (61). For immunoblot analysis, cells were washed in PBS and proteins extracted in 248 
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lysis buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1% NP-40 and 1x protease inhibitor 249 
cocktail (Roche) for 15 min on ice and clarified by centrifugation at 12,000 xg for 10 min, 4°C. 250 
For the detection of ARID3B by immunoblotting, we found that sonication prior to loading 251 
improved detection. SDS-PAGE and immunoblotting of normalized protein concentrations 252 
followed standard techniques using the following antibodies: rabbit pAb anti-FLAG-tag (1:1000; 253 
Sigma), mouse mAb anti-ORF57 207.6 (1:1000; Santa Cruz), RTA, rabbit antisera (1:400; gift 254 
from Prof. David Blackbourn, University of Surrey), mouse mAb anti-GAPDH (1:5000; Sigma), 255 
mouse mAb anti-Lamin B1 (1:1000; Santa Cruz), rabbit αARID3B (1:200; Abcam), anti-ORF59 256 
(Autogen Bioclear), sheep anti-KSHV minor capsid protein (mCP 1:1000; Exalpha Biologicals, 257 
Inc.). Proteins were detected by chemiluminescence (using HRP-conjugated secondary 258 
antibodies) and signals were captured digitally using the ChemiDoc MP Imager (Bio-Rad) that 259 
ensures signal saturation does not occur. ImageLab software version 4.1 (Bio-Rad) was used to 260 
select and determine the background-subtracted density of the bands in all blots and these 261 
were normalized against expression of GAPDH.  262 
Indirect immunofluorescence microscopy. As previously described (62), coverslips were coated 263 
with poly-L-lysine and TREx-BCBL-1-RTA cells were plated (1x106 per well of a 12-well plate) and 264 
doxycycline hyclate-treated (1 µg/ml) for 18 h at 37°C. Following doxycycline hyclate treatment 265 
of SILAC-labeled iRTA-293 cells (see above), coverslips were removed from the 10 cm dishes 266 
and placed in a humidity chamber. Cells were gently washed with PBS, fixed using 4% 267 
formaldehyde (in PBS) for 10 min, permeabilized with PBS, 1% Triton X-100 for 10 min and 268 
washed three times with PBS as previously reported (62). Primary antibodies were diluted in 269 
PBS, 2% BSA, added to cells and incubated in humidity chambers for 2 h at 37°C or overnight at 270 
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4°C followed by 5 washed with PBS. The appropriate secondary antibodies (Alexa Fluor 488 or 271 
594; Life Technologies) were diluted 1:500 in PBS, 2% BSA and incubated with cells for 1 h at 272 
37°C followed by 5 washed with PBS. Coverslips were mounted in VECTORSHEILD with DAPI 273 
(Vectorlabs).  274 
Incorporation of EdU was performed using a Click-iT EdU Imaging Kit (Life Technologies) (62). 275 
Briefly, 1x106 TREx-BCBL-1-RTA cells were treated doxycycline and the cells were plated onto 276 
poly-L-lysine-coated coverslips. After 16 h, cells were pulsed for 45 min with 10 μM EdU, 277 
washed, fixed and permeablized according to the manufacturer’s recommendations. After 278 
detection of EdU (according to the manufacturer’s protocol), the cells were washed and further 279 
incubated with the indicated antibody for 1 h at 37°C, washed again and incubated with Alexa 280 
Fluor 488 goat anti-rabbit antibody (Life Technologies; 1:500 in PBS, 2% BSA) for 1 h at 37°C. 281 
Finally, DNA was stained using Hoechst 33342 (1:2000 in PBS) and mounted in VECTORSHIELD 282 
(Vectorlabs). Images were captured using an LSM510 or LSM700 laser scanning microscope 283 
(Carl Zeiss) and processed using ZEN imaging software (Carl Zeiss). 284 
Antibodies included: rabbit anti-FLAG (1:250; Sigma), mouse anti-Myc tag 9E10 (1:250; Sigma), 285 
RTA rabbit antisera (1:100), rabbit anti-ARID3B (1:100; Abcam). 286 
Quantitative PCR. For RT-qPCR, total cellular RNA was extracted from cells using Trizol (Life 287 
Technologies) according to the manufacturer’s instructions and contaminating DNA was 288 
removed using the DNA-free kit (Ambion). Complimentary DNA (cDNA) was generated from 1 289 
μg RNA in 20 μl reaction volumes using M-MuLV reverse transcriptase (RT; New England Biolabs) 290 
according to the manufacturer’s recommendations with 5 ng oligo(dT). In parallel, negative 291 
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control reactions were performed for each RNA by omitting RT in order to confirm that 292 
quantification represented cDNA and not contaminating DNA. For quantification of viral DNA, 293 
1x106 cells were treated with doxycycline hyclate, or left untreated. At 72 h post-reactivation, 294 
total DNA was extracted using a DNA Minikit (Qiagen) and quantified by UV spectrophotometry. 295 
Viral DNA was quantified using primers specific for the ORF57 gene. Quantitative PCR reaction 296 
mixes (20 μl) included 1x SensiMix SYBR green master mix (Bioline), 0.5 μM each primer and 1 297 
μl cDNA or 3.4 ng total DNA. Cycling was performed in a RotorGene Q machine (Eppendorf) and 298 
included an initial 10 min denaturation step at 94°C, followed by 40 cycles of 30 s at 94°C, 30 s 299 
at 60°C and 30 s at 72°C. Melting curve analysis was performed between 65 and 95°C (with 300 
0.2°C increments) to verify amplicon specificity. Quantification of GAPDH mRNA (qRT-PCR) or 301 
GAPDH DNA (virus reactivation) was used to normalize between samples, and the average cycle 302 
threshold (CT) was determined from three independent samples from independent cultures. 303 
Calculations were made using the ΔΔCT method. 304 
RNAi. Conditions for siRNA knockdown of ARID3B followed previously reported protocols (57). 305 
Briefly, 20 nM of SMARTpool: ON-TARGETplus ARID3B siRNA (L-012219-00-0005, Dharmcon) or 306 
Hs_ARID3B_3 FlexiTube GeneSolution (GS10620, Qiagen), or scramble control siRNA (siRNA 307 
controls from the respective manufacturer were used as controls), were transfected into iSLK-308 
BAC16 cells for 72 h. For experiments that required reactivation of the lytic cycle, doxycycline 309 
was added to cells for 24 h, as stated above.  310 
In vitro DNA affinity assay. Assays were performed according to (25), with minor modifications:  311 
HEK293 rKSHV.219 cells in 6-well plates were transfected with pcDNA3-ARID3B-FLAG and the 312 
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lytic cycle was induced for 24 h. OriLyt sequences 3F, 9F and 11F were amplified from the KSHV 313 
genome using 5’-Biotinylated primers (primer sequences already described (25)) and a control 314 
region of the KSHV genome (RTA gene body: forward primer 5’-GTCTACCTTCCGAGGATTATGG-315 
3’, reverse primer : 5’-GATTCTGGCATGAGACCGCTTC-3’). PCR products were incubated with 316 
Dynabeads M-280 Streptavidin according to the manufacturer’s recommendations (Life 317 
Technologies). Affinity purification followed the previously described methods (25).  318 
Chromatin immunoprecipitation. Cells were cross-linked with 1% formaldehyde (Thermo 319 
Scientific, no. 28908) for 10 min at room temperature. Glycine was added to a final 320 
concentration of 125 mM to stop the cross-linking reaction, and the samples were incubated 321 
for another 5 min at room temperature. Cells were washed twice with ice-cold PBS and lysed in 322 
FastChIP buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 0.5 mM DTT, 0.5% Igepal 323 
CA-630, 1.0% Triton X-100) containing protease inhibitors (Roche) as described (63, 64). 324 
Isolated nuclei were resuspended in SDS lysis buffer (50 mM Tris-HCl [pH 8.1], 10 mM EDTA, 1% 325 
SDS) and the samples were incubated on ice for 15 min. Nuclear lysates were sonicated for 10 326 
min in a Diagenode Bioruptor Pico (30 sec on-off intervals) and cleared by centrifugation for 30 327 
min at 20,000×g and 4°C. Sheared chromatin from 9×106 cells (180µl) was combined with nine 328 
volumes of ChIP dilution buffer (16.7 mM Tris-HCl [pH 8.1], 167 mM NaCl, 1.2 mM EDTA, 1.1% 329 
Triton X-100, 0.01% SDS) and subjected to immunoprecipitation for 16 h at 4°C with gentle 330 
rotation using 13 µl of Rabbit anti-ARID3B antibody (Bethyl Laboratories, no. A302-564A-M) or 331 
4 µg of normal rabbit IgG. Samples were centrifuged for 10 min at 20,000×g, 4°C to remove any 332 
precipitated material, and the supernatants were combined with 20 µl Magna ChIP Protein A 333 
Magnetic Beads (Millipore, no. 16-661) and incubated for 2 h at 4°C with gentle rotation. 334 
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Immune complexes were washed with 1 ml each of low-salt buffer (20 mM Tris-HCl [pH 8.1], 335 
150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), high-salt buffer (20 mM Tris [pH 8.1], 336 
0.5 M NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS), lithium chloride (LiCl) buffer (10 mM Tris 337 
[pH 8.1], 0.25 M LiCl, 1 mM EDTA, 1% Igepal-CA 630, 1% deoxycholic acid), and twice with TE 338 
(10 mM Tris-HCl [pH 8.0], 1 mM EDTA) buffer. Elution of the chromatin-antibody complexes 339 
was carried out by incubation with 150 μl freshly prepared elution buffer (100 mM NaHCO3, 1% 340 
SDS) containing 1.5 µl Proteinase K (Roche, no. 03 115 887 001) at 62°C for 2 h, followed by a 10 341 
min incubation step at 95°C. DNA was purified using the NucleoSpin Gel and PCR Clean-up Kit 342 
from Macherey-Nagel (no. 740609) following their DNA clean-up protocol for samples 343 
containing SDS. DNA was eluted with 90 µl Buffer NE and 5 µl of the DNA solution were used as 344 
template DNA for qPCR using primers specific for the A/T-rich region of oriLyt left (forward 345 
primer: 5’-CCCTCCTTTGTTTTCCGGAAG-3’ and reverse primer: 5’CTCATCGGGCCCTATTATAAAG-346 
3’) and the RTA coding region (forward primer 5’-GTCTACCTTCCGAGGATTATGG-3’, reverse 347 
primer : 5’-GATTCTGGCATGAGACCGCTTC-3’). 348 
  349 
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Results 350 
ARID3B expression is enhanced by RTA. To investigate the impact of the lytic-switch protein 351 
RTA expression on the host proteome, we developed a cell line with doxycycline-inducible RTA 352 
expression (iRTA-293) and applied global proteomics using stable isotope labeling of amino 353 
acids in cell culture (SILAC). After metabolically labelling cells in media containing different 354 
stable isotopes of arginine (R) and lysine (K) (e.g. R10K8 (heavy) or R0K0 (light)) for two weeks, 355 
we induced RTA expression from heavy-labeled cells for 12 h while leaving light-labeled cells 356 
untreated. We tested RTA expression by immunofluorescence and then fractionated cells into 357 
cytoplasmic and nuclear fractions that were validated by immunoblot analysis using 358 
cytoplasmic and nuclear markers (Fig. 1A-B). Both these assays demonstrated the expected 359 
nuclear expression of RTA. We combined the nuclear fractions (heavy vs. light) 1:1 and applied 360 
LC-MS/MS (Dundee Cell Products, see Materials and Methods). Identified and quantified 361 
proteins with a minimum of two unique peptides and a fold change in abundance of >2-fold 362 
were taken forward for bioinformatics analyses. KEGG pathway analysis of the nuclear 363 
proteome of proteins increased in abundance upon RTA expression (using DAVID Bioinformatics 364 
Resources (59, 60)) identified various pathways one might expect to be modulated upon RTA 365 
expression (e.g. cell cycle control (65) and DNA replication (24); (Fig. 1C). However, various DNA 366 
damage response (DDR) pathways were also identified in addition to ubiquitin-mediated 367 
proteolysis (specifically Cullin-RING ubiquitin ligases [CRLs]). A cellular mechanism that 368 
regulates CRLs (66-68) and many of the listed DDR pathways (69-71) is the ubiquitin-like 369 
modification NEDDylation. Of note, we recently showed that blocking NEDDylation in cells 370 
latently infected with KSHV resulted in the activation RTA expression, but inhibited viral DNA 371 
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replication (62). Interestingly, a similar observation (with regards to effects on viral gene 372 
expression and viral DNA replication) was recently reported for the betaherpesvirus, human 373 
cytomegalovirus (HCMV); blocking of NEDDylation also led to increased immediate early gene 374 
expression in the absence of viral DNA replication (72). Furthermore, both of these reports 375 
showed that Cullin 4B was particularly important for regulating viral gene expression (62, 72). 376 
In addition to investigating cellular pathways associated with RTA expression, we compiled a list 377 
of the top 15 proteins that showed increases in abundance in RTA expressing cells (Table 1). 378 
Interestingly, a number of proteins associated with transcriptional repression were identified 379 
(cell division cycle-associated 7-like (15.5-fold increase), Polycomb group protein 380 
Lethal(3)malignant brain tumor-like protein 3 (5.7-fold increase) and lysine-specific 381 
demethylase 2A (5.2-fold increase)). We also note that RTA expression was associated with an 382 
increased abundance of protein LYRIC (7.0-fold increase) that has been shown to activate NF-κB 383 
(Table 1); intriguingly, these data suggest that RTA is associated with the expression of factors 384 
that one would predict to inhibit RTA’s transcriptional activity. In accordance with this, we also 385 
applied Ingenuity Pathways Analysis (IPA) to the same dataset, and the top canonical pathway 386 
identified, in addition to cell cycle control, DNA replication and various DNA damage pathways, 387 
was ‘transcriptional repression’ (Table 2). We are currently investigating some of these 388 
observations and in this report we focus on the novel protein ARID3B (7.5-fold increase). There 389 
are a number of features that led us to investigate ARID3B. Relatively little is known about this 390 
protein, and using KSHV as a tractable model system, we wished to further study its function. It 391 
has been shown that ARID3B functions as a transcription factor linked with prosurvival 392 
mechanisms during developmental processes (44-46), and these functions may be beneficial for 393 
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reactivation. Furthermore, ARID domains have been described as DNA binding domains that 394 
favor A/T-rich sequences; given the predominance of A/T-rich elements in regulatory regions of 395 
the KSHV genome (RREs, oriLyt etc.), we hypothesized that ARID3B would cooperate with RTA 396 
during reactivation of the lytic cycle.   397 
To investigate how RTA expression might lead to an increase in ARID3B levels, we induced RTA 398 
expression in iRTA-293 cells in addition to reactivating the lytic cycle in TREx-BCBL-1-RTA cells 399 
(see Materials and Methods for a description of the cell lines used in this study). We performed 400 
RT-qPCR analysis and found that RTA, and lytic reactivation, led to a small but reproducible 401 
increase in ARID3B mRNA expression (ca. 2.5-fold increase, Fig. 2A). We also reactivated the 402 
lytic cycle in iSLK-BAC16 and TREx-BCBL-1-RTA cells and performed immunoblot analyses using 403 
antibodies specific for ARID3B (Fig. 2B). This showed that lytic reactivation led to an 404 
approximate 1.5 - 2-fold increase in ARID3B expression (Fig. 2C). These changes are modest, but 405 
likely reflect the superior sensitivity of mass spectrometry, and the semi-quantitative nature of 406 
immunoblot data. Together, these data demonstrate that RTA, and the KSHV lytic cycle, 407 
enhances ARID3B expression at both the RNA and protein level. 408 
ARID3B is relocalized during reactivation. Given that ARID3B expression levels were influenced 409 
by RTA expression and lytic reactivation, we next asked whether it was involved in regulating 410 
the KSHV lytic cycle. Using an immunofluorescence microscopy approach, we showed that in 411 
latently infected TREx-BCBL-1-RTA cells, ARID3B expression displayed a pan-nuclear (excluding 412 
nucleoli) localization (Fig. 3A; -Dox. (latent)). However, upon lytic reactivation, ARID3B is 413 
relocalized to discrete, RTA-positive foci, with close proximity to the nuclear periphery (Fig. 3A; 414 
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+Dox. (lytic), compare the RTA-positive, reactivated cells to the RTA-negative cell in the same 415 
field of view), reminiscent of replication compartments (also known as replication and 416 
transcription compartments, RTCs). Replication compartments are distinct, RTA-positive foci 417 
found at the nuclear periphery associated with newly replicated viral DNA (that are observed 418 
via incorporation of BrdU or EdU that specifically marks viral DNA due to KSHV’s ability to block 419 
cellular DNA replication during reactivation). We performed an independent experiment to ask 420 
if ARID3B did indeed relocalize to these foci. Consequently, ARID3B was again shown to co-stain 421 
with RTA and to colocalize with EdU-positive foci (Fig. 3B) suggesting that it did indeed 422 
relocalized from a pan-nuclear pattern into KSHV replication compartments upon lytic 423 
reactivation.  424 
ARID3B modulates the KSHV lytic cycle. To investigate if ARID3B influenced the KSHV lytic cycle, 425 
we transfected iSLK-BAC16 cells with two separate pools of ARID3B-targeted or scramble 426 
control siRNAs and induced the lytic cycle with doxycycline for 24 h. Given that ARID3B has 427 
been suggested to function as a transcription factor, we anticipated that it might be important 428 
for enhancing RTA-mediated expression of lytic genes. Using RT-qPCR we demonstrated an 429 
approximately 50% knockdown of ARID3B. This was sufficient to enhance lytic gene expression 430 
between 1.5 – 2.5-fold, as shown for lytic genes ORF57 and gB (Fig. 4A), suggesting that ARID3B 431 
might actually inhibit lytic gene expression. We noticed that the two siRNAs had slightly 432 
different effects on lytic gene expression; these two siRNA preparations were mixtures of three 433 
different sequences, and it might be that one of these more potently targets ARID3B. However, 434 
we cannot fully explain this as the current time, and this difference was not observed in other 435 
assays with this set of siRNAs. ARID3B knockdown was also associated with an approximate 2-436 
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fold increase in lytic protein expression (Fig. 4B-C). Accordingly, ARID3B knockdown, followed 437 
by reactivation of the lytic cycle, also led to a significant enhancement of KSHV genome 438 
replication compared to cells transfected with a scramble control siRNA (Fig. 4D). Importantly, 439 
knockdown in latently infected cells did not activate viral DNA replication (Fig. 4D) suggesting 440 
that RTA expression, or the lytic cycle were required to activate ARID3B’s inhibitory properties.  441 
To ask if the increases in lytic cycle-associated expression and genome replication led to an 442 
enhanced productive infection, we harvested and clarified media from iSLK-BAC16 cells that 443 
had been transfected with ARID3B siRNA and reactivated with doxycycline. We transferred this 444 
media to KSHV-negative cells (HEK 293T), and 24 h later, purified total cellular RNA. Using RT-445 
qPCR analysis of the KSHV ORF57 gene as a measure of virus infection, we demonstrated 446 
knockdown of ARID3B led to an enhancement of virus infection, suggesting that ARID3B 447 
knockdown led to an increase of released virions (Fig. 4E). Together, these data showed that 448 
ARID3B knockdown enhanced the KSHV lytic cycle, contrary to our initial hypothesis. However, 449 
these differences were modest given our inability to reduce ARID3B expression more than 50-450 
60%. Therefore, we took an alternative approach and asked if ARID3B overexpression could 451 
inhibit KSHV reactivation. Here we showed that transfection of FLAG-tagged ARID3B, but not 452 
FLAG-SRAG (used as a control as we know its expression does not modulate lytic reactivation), 453 
in iSLK-BAC16 cells for 24 h, followed by reactivation of the lytic cycle, inhibited the expression 454 
of KSHV lytic genes (Fig. 4F). Together, these data demonstrate that ARID3B is able to modulate 455 
KSHV reactivation, and not enhance it, as originally predicted. 456 
 457 
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ARID3B interacts with an A/T-rich region of oriLyt in a lytic reactivation-dependent manner. 458 
To investigate a potential mechanism whereby ARID3B tempered KSHV lytic reactivation, we 459 
tested the possibility that ARID3B interacted with RTA and inhibited its function. RTA interacts 460 
with various cellular proteins that are known to be inhibitory, including PARP1 (34), TLE2 (33) 461 
and HDAC1 (35). However, co-immunoprecipitation assays demonstrated that while RTA 462 
interacted with a known binding partner ORF59 (22), it did not interact with ARID3B (Fig. 5). 463 
Next, we reasoned that ARID3B, as a DNA binding protein, might interact with viral genomes. 464 
Furthermore, due to its predicted preference for A/T-rich sequences, and the existence of these 465 
sequences in oriLyt, we focused our attention to this region of the KSHV genome. We 466 
performed a DNA affinity assay that has previously been reported as a method for identifying 467 
proteins involved in KSHV reactivation (25). Biotinylated PCR products that spanned oriLyt were 468 
amplified from KSHV DNA (Fig. 6A) were bound to streptavidin-coated beads and incubated 469 
with lysate from reactivated HEK293T-rKSHV.219 cells that had been transfected with FLAG-470 
ARID3B 24 h earlier. Compared to control DNA (amplified from the RTA coding region), and a 471 
central G/C-rich repeat region (“9F”) we found that ARID3B preferentially bound to “3F” which 472 
contains the A/T-rich region of KSHV oriLyt (Fig. 6A). ARID3B also bound to “11F” which 473 
contained the RTA-responsive element (RRE), although this appeared to be slightly reduced 474 
when compared to the 3F region. Interestingly, it was shown previously that many host and 475 
viral proteins involved in KSHV reactivation specifically bind these two regions in oriLyt (25). 476 
 We confirmed this result using chromatin immunoprecipitation (ChIP) assays using TREx-BCBL-477 
1-RTA cells. This allowed to us investigate whether ARID3B interacted with the KSHV genome in 478 
infected cells, in addition to asking if this was linked with reactivation of the lytic cycle. Using an 479 
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antibody that has previously used in ChIP assays (43), we showed that endogenous ARID3B 480 
interacted preferentially with the A/T-rich region of oriLyt (3.5-fold enrichment over control IgG 481 
antibody), and not within the RTA gene (Fig. 6B). Furthermore, we showed that this interaction 482 
was dependent on reactivation of the KSHV lytic cycle as no binding (above control IgG 483 
antibody) was observed in latent cells (Fig. 6B). These data, together with data in Fig. 2 (lytic 484 
cycle-associated relocalization) and Fig. 4 (knockdown of ARID3B does not induce viral DNA 485 
replication), suggest that ARID3B influences KSHV biology only upon reactivation of the lytic 486 
cycle. 487 
  488 
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Discussion. 489 
It is well established that KSHV is the etiologic agent of various malignancies in immune-490 
compromised individuals, particularly those infected with HIV. Indeed, KS is the most prevalent 491 
malignancy in regions with endemic HIV and, for HIV sufferers, is one of a number of diseases 492 
that are used as a guideline for the diagnosis of AIDS (i.e. KS is considered an AIDS-defining 493 
disease) (2). Importantly, various reports, including data from clinical studies, link reactivation 494 
of the KSHV lytic cycle with the pathogenesis of KS. Therefore, it is imperative that we 495 
understand the mechanisms that regulate this aspect of KSHV biology. RTA, the KSHV lytic 496 
switch protein, is both necessary and sufficient for reactivation of the lytic cycle (8). While we 497 
have a relatively good understanding of how RTA drives the viral transcriptional program 498 
responsible for lytic reactivation (8), how RTA influences cellular responses is less well 499 
understood. In this report we developed a cell line with inducible RTA expression and, by 500 
applying a quantitative proteomics approach, used it to investigate what impact RTA expression 501 
has on the cellular proteome. 502 
We identified a number of cellular pathways that were associated with RTA expression, and 503 
some of these are the focus of current research. Of note, ubiquitin-mediated proteolysis was 504 
one of the gene ontology terms included in our bioinformatics analyses. We, and others, have 505 
recently reported the importance of this pathways for regulating herpesvirus gene expression, 506 
and demonstrated that this pathway represents a potential therapeutic target for the 507 
treatment of herpesvirus disease (62, 72). In addition to studying cellular pathways, we 508 
generated a list of the top 15 proteins based on increased protein abundance in RTA-expressing 509 
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cells. In this report, we focused on a little-known protein ARID3B. We initially hypothesized that, 510 
as a prosurvival transcription factor (43, 44), this protein would cooperate with RTA during 511 
reactivation of the lytic cycle. However, we actually found that ARID3B played an inhibitory role, 512 
and its expression was associated with modulating lytic reactivation. 513 
A hallmark of all herpesviruses is their ability to establish a latent infection characterized by a 514 
highly restricted gene expression program. This is an incredibly effective means of evading 515 
detection by the immune system, and ensures infection is maintained throughout the life of the 516 
host. Nevertheless, periodic reactivation of the lytic cycle is necessary in order to maintain the 517 
population of infected cells. However, the lytic cycle must be exquisitely regulated so that it 518 
does not lead to uncontrolled virion production and severe disease in its host. We observed 519 
that upon RTA expression, or reactivation of the lytic cycle, ARID3B expression was increased 520 
both at the mRNA and protein level. To ascertain if this had functional consequences for KSHV 521 
reactivation, we performed a series of experiments that showed ARID3B was able to block 522 
reactivation. This included siRNA-mediated knockdown of ARID3B, which resulted in enhanced 523 
lytic gene expression, lytic protein expression and an increase in genome replication. 524 
Furthermore, knockdown of ARID3B potentially led to an increase in virion production, as 525 
suggested by reinfection assays. As an alternative approach, overexpression of ARID3B 526 
significantly abrogated lytic protein expression. Importantly, knockdown of ARID3B in latently 527 
infected cells did not reactivate the lytic cycle, suggesting that it was not involved in the 528 
maintenance of latency. Therefore, RTA-mediated activation of ARID3B specifically served to 529 
regulate lytic reactivation; however, it is also possible that this inhibitory function may be 530 
important during the establishment phase of latency.  531 
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KSHV reactivation leads to the upregulation of several negative feedback processes that temper 532 
the lytic cycle, many of which center on abrogating RTA’s interaction with RBP-Jκ (required for 533 
transactivating various lytic gene promoters via the ‘indirect’ mechanism (8)). For example, and 534 
in a similar vein to the observed RTA-enhanced ARID3B expression, RTA enhances the 535 
expression of the co-repressor transducin-like enhancer of split 2 (TLE2) that blocked lytic 536 
reactivation by competing with RBP-Jκ for the same binding site in RTA (33) (we did not identify 537 
TLE2 in our datasets). Lytic reactivation also promotes nuclear translocation of the transcription 538 
factor NF-κB, which in turn negatively regulates lytic cycle-associated gene expression by 539 
competing with RTA for RBP-Jκ binding (32, 73, 74). Furthermore, activated NF-κB is required 540 
for the expression of latency-associated genes (e.g. LANA, vFLIP, vCyclin), and LANA has been 541 
shown to inhibit lytic reactivation, again, by interfering with RTA-RBP-Jκ interactions (75, 76). 542 
Additional negative regulatory mechanisms involve RTA interactions with histone deacetylase 543 
enzymes HDAC1 (35) and SIRT1 (77), which limits RTA’s ability to activate lytic gene 544 
transcription. We do not currently know how RTA led to increases in ARID3B expression. As a 545 
transcription factor, RTA may drive the expression of ARID3B; it may also be possible that RTA 546 
induces ARID3B expression indirectly. Here, two possibilities exist: i) RTA expression may 547 
promote a cellular response that is linked to ARID3B expression or ii) RTA may sequester a 548 
repressor that would normally silence ARID3B. As there are no reports describing the regulation 549 
of ARID3B expression, it is not possible to go beyond speculation.  550 
Commencement of the lytic cycle leads to a dramatic remodelling of the cell nucleus and the 551 
formation of discrete foci (termed replication compartments) where viral transcription, genome 552 
replication and capsid assembly takes place (78). For KSHV, the formation of replication 553 
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compartment was recently shown to be dependent on the chaperone function of Hsp70 554 
proteins  (57). We observed that, upon lytic reactivation, ARID3B relocalized from a pan-nuclear 555 
pattern, to replication compartments as shown by its colocalization with RTA and EdU. Of note, 556 
it was also recently shown that lytic reactivation induced the relocalization of TLE2 in to 557 
replication compartments (33), highlighting a common feature among negative regulators of 558 
the lytic cycle. This suggested that ARID3B might inhibit reactivation by interacting with a 559 
protein required for lytic reactivation (cellular or viral), or the viral genome, although these 560 
scenarios are not necessarily mutually exclusive. Interestingly, RTA and ARID3B did not interact. 561 
This was somewhat surprising; however, as a DNA binding protein, an interaction with RTA may 562 
not be necessary for it to associate with reactivated KSHV. Therefore, unlike the majority of 563 
lytic cycle regulators that have been shown to interact directly with RTA, ARID3B performs this 564 
task via a different mechanism. 565 
We reasoned that ARID3B, as a DNA binding protein, might interact with viral genomes. 566 
Particularly, given its proposed preference for A/T-rich sequences and the presence of these 567 
sequences in oriLyt, we considered the possibility that ARID3B binds to this region of the 568 
genome. Indeed, DNA affinity (Fig. 6A) and ChIP assays (Fig. 6B) demonstrated that this was the 569 
case. The DNA affinity assay showed us that overexpressed ARID3B preferentially bound to a 570 
region of oriLyt that also contains A/T-rich palindromic sequences in addition to a downstream 571 
region which contained the RTA-responsive element (RRE). Interestingly, it was previously 572 
shown that many host and viral proteins involved in KSHV reactivation specifically bind these 573 
two regions in oriLyt (25). 574 
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Importantly, ChIP assays not only allowed us to confirm binding in vivo, it also allowed us to ask 575 
if its interaction was dependent on lytic reactivation. This was an important question as much 576 
of our data suggested that ARID3B’s inhibitory properties were associated with RTA expression, 577 
which is silenced during latency; for example, and as mentioned earlier, knockdown of ARID3B 578 
from latently-infected cells did not appear to stimulate lytic gene expression (suggesting it does 579 
not have a role in the maintenance of latency). Strikingly, this interaction was indeed 580 
dependent on reactivation of the lytic cycle, as no binding was observed on the latent genome. 581 
This might suggest that the chromatinized latent KSHV genome precludes ARID3B access; 582 
however, upon reactivation, which is associated with removal of nucleosomes, ARID3B can bind. 583 
However, it is not currently known if ARID3B binding is dependent on chromatin status of DNA. 584 
Additionally, whether this is dependent on direct DNA binding or it requires PPIs, and if ARID3B 585 
blocks transcription or DNA replication are still open questions. Nevertheless, this data provides 586 
weight to the hypothesis that ARID3B specifically responds to reactivation of the lytic cycle 587 
from latency and inhibits it via interactions with the KSHV genome. We propose that this 588 
interaction likely competes with oriLyt-associated factors required for reactivation of the lytic 589 
cycle (Fig. 7). 590 
We were surprised to observe that RTA expression induced a number of proteins and pathways 591 
associated with transcriptional silencing (Tables 1 and 2). Although it will be critical to validate 592 
these observations, this might not be surprising given that de novo KSHV infection of tissue 593 
culture cells leads to viral latency, despite an initial burst of lytic cycle-associated gene 594 
expression (79). Therefore, while RTA drives expression from the viral genome during 595 
 o
n
 August 22, 2016 by UNIVERSITY O
F LEEDS
http://jvi.asm.org/
D
ow
nloaded from
 
31 
 
reactivation, it may also induce a number of processes (directly or indirectly) that ultimately 596 
silences lytic gene expression.  597 
In summary, we have identified a novel cellular protein, ARID3B, which responds to the lytic 598 
cycle of KSHV, and functions to inhibit it.  Lytic cycle-associated induction of negative feedback 599 
mechanisms is clearly an important feature of herpesvirus biology and is consistent with a virus 600 
that favors lifelong infection of its host. 601 
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Figure legends 834 
FIG 1. Analysis via SILAC coupled to LC-MS/MS of nuclear proteome changes in response to 835 
KSHV-RTA expression. Flp-In-293 cells were used to develop a cell line with doxycycline-836 
inducible FLAG-tagged RTA expression (iRTA-293). (A) Cells were labeled with R10K8 (heavy) or 837 
R0K0 (light) labelled SILAC media for two weeks. FLAG-RTA expression was induced in heavy-838 
labelled cells for 12 h and these were fractionated into nuclear and cytoplasmic compartments. 839 
Fractionation success was validated by immunoblot analysis using the nuclear (Lamin-B1) and 840 
cytoplasmic (GAPDH) markers. As expected, RTA expression was largely restricted to the 841 
nuclear compartment, and was only found in dox.-treated cells. (B) FLAG-RTA expression was 842 
analyzed by confocal immunofluorescence that revealed all Dox.-treated cells were positive for 843 
FLAG-RTA and Untreated (-Dox; R0K0-labeled cells) were negative for RTA expression, 844 
demonstrating tight regulation of FLAG-RTA. Scale bar - 10 µm. (C) KEGG pathway analysis of 845 
nuclear proteins that were upregulated 2-fold or more due to RTA expression, with at least 2 846 
independent peptides revealed various cellular pathways associated RTA expression. GO Term – 847 
gene ontology term. 848 
 849 
FIG 2. RTA enhances ARID3B expression. (A) Doxycycline- (Dox.)-induced expression in iRTA-293 850 
cells for 12 h and reactivation of the KSHV lytic cycle by the addition of Dox. in TREx-BCBL1-RTA 851 
cells increased ARID3B expression as measured by qRT-PCR. Error bars represent standard 852 
deviation from the mean from three independent biological replicates and quantification was 853 
normalized to GAPDH using the ΔΔCt method. Student’s t-tests were used to determine 854 
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statistical significance. Three independent experiments were performed for each cell line (B) 855 
Reactivation of the lytic cycle from latently infected iSLK-BAC16 and TREx-BCBL1-RTA cells led 856 
to an increase in ARID3B protein expression. In this experiment, separate immunoblots were 857 
used for the detection of RTA (denoted by a line). (C) Quantification of protein expression in (B) 858 
(see Materials and Methods). Data are derived from two independent experiments and error 859 
bars represent standard deviation of the mean (calculated from technical replicates within 860 
independent experiments). * = P < 0.05 (Student’s t-test). 861 
FIG 3. ARID3B relocalizes to KSHV replication compartments upon reactivation of the lytic cycle. 862 
(A) Confocal immunofluorescence analysis demonstrated that ARID3B relocalized to discrete, 863 
RTA-positive foci that resemble replication compartments (white arrows) upon Dox.-induced 864 
reactivation of the KSHV lytic cycle in TREx-BCBL1-RTA cells. (B) Further evidence suggesting 865 
that ARID3B relocalized to replication compartments demonstrated by its colocalization with 866 
RTA and EdU-positive foci (white arrows). EdU is used as a marker of newly replicated viral (57). 867 
Scale bar - 10 µm. 868 
FIG 4. ARID3B inhibits KSHV lytic reactivation. (A) Latently infected iSLK-BAC16 cells were 869 
independently transfected with two separate siRNAs pools targeting ARID3B (or a non-targeting 870 
scramble control siRNA) for 72 h and then reactivated by addition of dox (a further 24 h; see 871 
Materials and Methods). RT-qPCR was used to quantify ARID3B, ORF57 and gB levels and the 872 
fold difference in expression was compared to scramble control using GAPDH levels to 873 
normalize between samples. Error bars represent standard deviation from the mean from two 874 
independent experiments, with mean values calculated from the technical replicates of each 875 
experiment. Statistical analyses demonstrated a significant increase in lytic gene expression in 876 
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siARID3B-treated cells compared to scramble control ** p = <0.0001 (Student’s t-test). (B) 877 
Knockdown of ARID3B led to an enhancement of lytic protein expression. (C) Quantification of 878 
(B) (see Materials and Methods). (D) Knockdown of ARID3B enhanced viral genome replication. 879 
ARID3B siRNA or scramble control siRNAs transfection of iSLK-BAC16 cells followed by 880 
reactivation of the lytic cycle for 72 h led to an increase in viral genome replication, as 881 
quantified by qPCR of the KSHV ORF57 gene. Cellular GAPDH was used to normalize between 882 
samples and error bars represent standard deviation from the mean from three independent 883 
biological replicates (* p < 0.05). (E) Knockdown of ARID3B enhances virion production. Media 884 
from iSLK-BAC16 cells that had been transfected with siARID3B or scramble control siRNAs were 885 
used to infect KSHV-negative HEK293T cells. As a measure of infection, RT-qPCR analysis of the 886 
KSHV lytic gene ORF57 was performed 24 h following infection. Data represent three 887 
independent infections in a single experiment, and Student’s t-test was used to determine 888 
statistical significance (* = P < 0.05). (F) Overexpression of FLAG-ARID3B inhibits reactivation of 889 
lytic cycle-associated protein expression. Expression vector containing FLAG-tagged ARID3B 890 
(FLAG-ARID3B) or FLAG-SRAG (used as a negative control) were transfected in to iSLK-BAC16 891 
cells for 24 h, followed by Dox.-induced reactivation of the KSHV lytic cycle. Cell lysates were 892 
harvested 24 h later and subjected to immunoblot analysis of lytic proteins ORF57 and mCP 893 
(minor capsid protein).  894 
FIG 5. RTA and ARID3B do not directly interact. Immunoprecipitation assay showing RTA 895 
interacts with known binding partner ORF59, but not ARID3B. The lytic cycle was induced in 896 
ARID3B-transfected iSLK-BAC16 cells. Proteins were immunoprecipitated with the indicated 897 
antibodies followed by immunoblot analysis. 898 
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FIG 6. ARID3B interacts with the KSHV genome in a lytic reactivation-dependent manner. (A) 899 
DNA affinity assays performed according to (25); biotinylated PCR products spanning oriLyt left 900 
of KSHV (GenBank accession number: NC_009333.1) and control DNA amplified from the RTA 901 
coding region were bound to streptavidin Dynabeads and incubated with lysates from 902 
reactivated 293T rKSHV.219 cells expressing FLAG-ARID3B. This suggested ARID3B bound these 903 
sequences with preference for the A/T-rich region. (B) TREx-BCBL1-RTA cells were treated with 904 
doxycycline for 18 h (w/ Dox) to reactivate the lytic cycle or were left untreated (w/o Dox). 905 
Samples were subjected to ChIP with an antibody to ARID3B or normal rabbit IgG and primers 906 
specific for sequences in the A/T-rich region of oriLyt or the RTA coding region. The percentage 907 
of output versus input DNA was calculated and is presented relative to normal rabbit IgG values 908 
from unreactivated (w/o Dox) cells (set to 1). Data represent two biological (i.e. independent 909 
ChIPs) and two technical replicates per ChIP from a single experiment, and values are given as 910 
the mean ± standard deviation. Student t-tests were used to determine statistical significance. 911 
FIG 7. A model of how ARID3B inhibits lytic reactivation. Periodic reactivation of KSHV involves 912 
replication of the viral genome and the production of new virions, a necessary step for the 913 
maintenance of latency and the pathogenesis of KS (2). Viral DNA replication initiates from the 914 
cis-acting oriLyt where proteins essential for this process are recruited. These include viral 915 
proteins RTA, K8 and the six core proteins (DNA polymerase, DNA processivity factor etc.) (80) 916 
in addition to various cellular trans-acting proteins (25). We hypothesize that during 917 
reactivation RTA is expressed leading to the enhanced expression of ARID3B and its recruitment 918 
to viral genomes, specifically AT-rich elements such as those found in oriLyt. ARID3B may 919 
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compete with factors required for reactivation for binding with the KSHV genome in order to 920 
modulate the levels of reactivation or for the establishment of latency. 921 
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